Results 131 to 140 of about 2,290 (211)

USP30 inhibits wound healing in diabetic foot ulcers by promoting TRAF6‐induced ferroptosis and angiogenesis inhibition

Journal of Diabetes Investigation, EarlyView.
High glucose upregulates USP30 in HUVECs, which deubiquitinates and stabilizes TRAF6. Stabilized TRAF6 suppresses GPX4 and SLC7A11, increases ROS/MDA/lipid peroxidation, and activates ferroptosis and apoptosis, leading to impaired angiogenesis and delayed wound healing.
Jingjing Yuan, Shuang Sui, Zhenghua Yang, Kaiwen Zhang, Qiang Hu   +4 more
wiley   +1 more source

Effects of dipeptidyl peptidase‐4 inhibition in vivo: Dipeptidyl peptidase‐4 inhibitor/gut microbiome crosstalk suggests novel therapeutic options for diabetes management

Journal of Diabetes Investigation
Takuma Yasuda, Norio Harada, Nobuya Inagaki   +2 more
doaj   +1 more source

Cardiovascular preventive role of thiazolidinedione in patients with type 2 diabetes mellitus undergoing percutaneous coronary intervention

Journal of Diabetes Investigation, EarlyView.
Among patients with type 2 diabetes undergoing percutaneous coronary intervention, thiazolidinedione use was independently associated with a significantly reduced risk of a composite of myocardial infarction, stroke, and all‐cause death, notably without an increased risk of admission for heart failure. ABSTRACT Background Thiazolidinediones (TZD) are a
Jinkwon Kim, Jimin Jeon, Joonsang Yoo, Minyoul Baik, Seok‐Jae Heo, Ji Woong Roh   +5 more
wiley   +1 more source

Sodium zirconium cyclosilicate compared with potassium restriction for hyperkalemia management in type 2 diabetes: The SILVERSTAR trial

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Aims/Introduction To demonstrate noninferiority of continued sodium zirconium cyclosilicate therapy versus a potassium‐restricted diet in achieving normokalemia at Visit 7 (Days 28–42) in individuals with type 2 diabetes and hyperkalemia, using a noninferiority margin of −10 percentage points (one‐sided α = 0.025).
Masahide Hamaguchi, Junya Hironaka, Hiroshi Okada, Mari Yoneda, Ayaka Kobayashi, Yoshitaka Hashimoto, Aya Kitae, Noriyuki Kitagawa, Akio Kishi, Michiyo Ishii, Mai Asano, Masahiro Yamazaki, Toru Tanaka, Hanako Nakajima, Eiko Sato, Michiaki Fukui   +15 more
wiley   +1 more source

Insulin‐reducing effect of adding imeglimin to ongoing dipeptidyl peptidase‐4 inhibitor therapy with multiple daily insulin injections (INSPIRE study)

Journal of Diabetes Investigation, EarlyView.
ABSTRACT Introduction Simplifying multiple daily insulin injections (MDI) has attracted great interest in clinical practice. Although imeglimin shows good compatibility with dipeptidyl peptidase‐4 inhibitors (DPP‐4i), its effectiveness in patients treated with MDI remains unclear.
Atsushi Itsukaichi, Fukumi Yoshikawa, Manabu Saito, Ayako Fuchigami, Yoko Iwata, Genki Sato, Hiroshi Uchino, Takahisa Hirose   +7 more
wiley   +1 more source

Dipeptidyl peptidase-4 (DPP-4; CD26) [PDF]

Science-Business eXchange, 2014
openaire   +1 more source

The miR‐145‐5p/NRF2/SLC7A11 axis regulates ferroptosis‐mediated renal tubular epithelial cell injury in diabetic nephropathy

Journal of Diabetes Investigation, EarlyView.
Suppression of miR‐145‐5p alleviates DN‐associated renal tissue damage by inhibiting NRF2/SLC7A11‐mediated ferroptosis of RTECs. ABSTRACT Purpose This study aimed to investigate the molecular mechanism by which the miR‐145‐5p/NRF2/SLC7A11 axis regulates ferroptosis‐mediated renal tubular epithelial cell (RTEC) injury in diabetic nephropathy (DN ...
Ganlin Wu, Yu Fang, Meirong Xu, Zuopeng Lu, Yu Cao, Yana Gao   +5 more
wiley   +1 more source

Diagnostic performance of SD‐ΔRR during physical stressors for identifying diabetic sensorimotor polyneuropathy

Journal of Diabetes Investigation, EarlyView.
Study population, methodology and key findings of the study. ABSTRACT Aims This study aimed to evaluate the clinical efficacy of SD‐ΔRR as a novel methodology for short‐duration heart rate variability (HRV) assessment for the diagnosis of diabetic sensorimotor polyneuropathy (DSPN) in patients with diabetes.
Katsuyoshi Katayama, Haruhito A. Uchida, Toshihiko Nagao, Jun Eguchi, Kenji Tsuji, Yoshinori Matsumoto, Ichiro Nojima, Keiko Tanaka, Hidemi Takeuchi, Yasuhiro Onishi, Rika Takemoto, Satoshi Miyamoto, Kenichi Shikata, Jun Wada   +13 more
wiley   +1 more source

Serum‐derived microribonucleic acids as potential novel biomarkers for slowly progressive type 1 diabetes mellitus

Journal of Diabetes Investigation, EarlyView.
This study evaluated serum miRNAs as biomarkers in adult patients with SPIDDM. Serum miRNAs were measured at the time of SPIDDM (probable) diagnosis, and miR‐150‐5p was inversely associated with CPI at the last outpatient visit, suggesting its potential utility for predicting subsequent insulin secretory decline.
Hideyuki Okuma, Takahiro Tsutsumi, Masashi Ichijo, Tetsuro Kobayashi, Kyoichiro Tsuchiya   +4 more
wiley   +1 more source

Dipeptidyl Peptidase-4 Inhibitors

Circulation Journal, 2013
openaire   +3 more sources